Why is Celldex Therapeutics stock plummeting today?
Celldex Therapeutics (CLDX) stock fell 37% in pre-market trading after positive Phase 3 trial results for barzolvolimab, a 'sell the news' reaction. The trials met primary and secondary endpoints, but investors were disappointed, as the stock had rallied ahead of the announcement. The company's Phase 2 study failure and delayed BLA submission also contributed to the decline. The broader market showed little impact, indicating the drop was company-specific.
How this was made
The 30-second read
Why it matters
The news triggered a sharp intra‑day price decline, reflecting a classic binary‑event reversal where the catalyst did not exceed the inflated price expectations.
Market read
Primary relevance is to CLDX shareholders; broader market impact is minimal.
What to watch
Potential future BLA filing in 2027 and prior Phase 2 failure in prurigo nodularis may limit upside.
Background
Celldex announced positive topline Phase 3 data for barzolvolimab in chronic spontaneous urticaria, but the market reacted negatively due to high prior expectations and a recent Phase 2 failure.
Ticker impact
Celldex Therapeutics stock plunged 37% in pre‑market after announcing Phase 3 trial results for barzolvolimab.
Further short pressure likely; watch for support around $22‑$23.
The abrupt 37% drop on same‑day news indicates strong trader reaction; no mitigating catalysts were mentioned.
Market effects
Inflammatory disease biotech sector may see heightened scrutiny on trial expectations.
U.S. biotech stocks could face short‑term pressure.
Limited to biotech investors; no broad market effect.
Counterpoint
If the trial data are truly positive, the sell‑off may be an overreaction and a buying opportunity at lower levels.
Key entities
- CompanyCelldex Therapeutics
Biopharma developing barzolvolimab for chronic spontaneous urticaria.
